First Day on Retatrutide: Trial Data and Risks

Retatrutide is an investigational triple receptor agonist developed by Eli Lilly that has no marketing authorisation in the UK or elsewhere. For anyone enrolled in an authorised clinical trial, the first day on retatrutide marks the beginning of a carefully monitored, protocol-driven process. This article explains what retatrutide is, what early-phase trial data have reported about initial dosing, which side effects have been observed in trials, and why sourcing this medicine outside an authorised clinical trial carries serious health risks. All information here is drawn from published trial data and is intended to inform, not to promote.

What is retatrutide and what is its current status in the UK?

Retatrutide is an investigational triple agonist (GLP-1, GIP and glucagon receptors) with no UK or global marketing authorisation; it can only be accessed within an authorised clinical trial.

Retatrutide holds no marketing authorisation in the UK or anywhere else, meaning it cannot be prescribed or supplied outside an authorised clinical trial.^[15][10] It is an investigational medicine developed by Eli Lilly that acts simultaneously on three hormone receptors: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor.^[1][2] This triple agonist mechanism is designed to influence appetite regulation, energy expenditure and glucose metabolism through complementary pathways. Because it targets three receptors rather than two (as tirzepatide does) or one (as semaglutide does), researchers have been investigating whether this broader hormonal engagement produces different metabolic effects. No head-to-head trials comparing retatrutide directly with currently licensed weight-management medicines have been published to date, and readers wishing to verify this should consult the ClinicalTrials.gov and ISRCTN registries.

The MHRA has not authorised retatrutide, and no regulatory submission date or approval timeline has been publicly announced by the MHRA or the European Medicines Agency.^[15] Anyone in the UK who encounters retatrutide being sold or offered outside a formal clinical trial should be aware that such a product is not a licensed medicine and may be falsified or unsafe. If you are interested in licensed weight-management treatments, these can be discussed with your GP.

What did early-phase trials report about the first doses?

Phase 2 trial data (NEJM 2023) reported that participants started on low doses escalated gradually over a structured titration period within a tightly controlled research setting.

Early-phase trial data for retatrutide, including findings from the Phase 2 programme published in the New England Journal of Medicine in 2023, reported that participants receiving the medicine in a controlled trial setting began at low starting doses that were escalated gradually over a structured titration period.^[1][2] The Phase 2 trial enrolled adults with obesity or overweight and followed participants over 48 weeks.^[1][2] At the lowest dose levels studied, the trial reported modest early effects on body weight, with more pronounced reductions observed at higher doses reached later in the titration schedule. Phase 3 programmes, including TRIUMPH (obesity) and TRANSCEND (type 2 diabetes), have since reported further data across broader populations; however, as full peer-reviewed publications for these programmes are still emerging, specific findings should be sought from the primary sources once available rather than from summaries.^[4][5]

It is important to understand that these findings describe outcomes within a tightly controlled research environment, with regular clinical monitoring, standardised dose escalation protocols and defined eligibility criteria. Titration schedules are protocol-specific and cannot be generalised outside the trial setting. Participants were screened carefully before enrolment, and those who were pregnant, breastfeeding, planning pregnancy or who did not meet specific health criteria were excluded from participation, consistent with the precautionary approach taken when studying any investigational medicine in people of childbearing potential. Trial results cannot be directly extrapolated to what an individual might experience, and the data should be interpreted as research findings rather than predictors of personal outcomes.

What side effects have been observed in retatrutide trials?

The most commonly reported side effects were gastrointestinal, including nausea, vomiting and diarrhoea; acute pancreatitis and heart rate increases were also observed in Phase 2 data.

The most commonly reported side effects in retatrutide trials have been gastrointestinal in nature, consistent with the GLP-1 receptor agonist component of its mechanism. Across the Phase 2 trial (NEJM 2023), nausea, vomiting, diarrhoea and constipation were among the adverse events reported most frequently, particularly during the dose escalation phase. These effects were generally described as mild to moderate in severity and tended to decrease over time as participants progressed through the titration schedule. Injection-site reactions were also reported in some participants.

More serious adverse events observed in the Phase 2 trial included cases of acute pancreatitis, which has been reported with medicines in this drug class more broadly. Heart rate increases were also noted in the trial data, a finding that has been observed with other GLP-1 receptor agonists.^[1][2] As with all investigational medicines, the full safety profile of retatrutide will not be established until larger and longer-term studies are completed and reviewed by regulatory authorities.

Participants in clinical trials are monitored closely throughout, and any suspected adverse events should be reported to the trial team under the study protocol. If you are enrolled in a trial, you should carry your trial identification card and study contact details at all times, and inform any urgent or emergency clinician that you are participating in a clinical trial so that they can take this into account when assessing and treating you. If you experience any concerning symptoms while enrolled in a trial, contact your trial team promptly. For urgent medical concerns, call NHS 111 or attend your nearest emergency department. Suspected side effects of a medicine you are taking outside a trial can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

What are the risks of sourcing retatrutide outside a clinical trial?

Products sold outside authorised trials as retatrutide have no regulatory oversight and may be falsified or contaminated; there is no legitimate route to obtain retatrutide in the UK outside a clinical trial.

Sourcing retatrutide outside an authorised clinical trial carries serious health risks, because retatrutide can only be prescribed or supplied within such a trial and any product sold through other channels is not a licensed medicine. Products marketed online as retatrutide have no regulatory oversight, no verified manufacturing standards and no guarantee of content, purity or sterility. Falsified injectable medicines in particular carry risks of contamination, incorrect dosing and the introduction of harmful substances. The MHRA regularly warns the public about the dangers of purchasing unlicensed medicines online, and NHS guidance reinforces that buying prescription medicines from unregulated sources is unsafe; injectable products obtained from unregulated sources pose especially significant risks.^[16]

Beyond the physical risks of the product itself, using an unverified injectable substance without clinical supervision means there is no monitoring for adverse effects, no structured dose escalation and no access to medical support if something goes wrong. The safety measures built into clinical trials, including regular assessments, laboratory monitoring and defined stopping criteria, exist precisely because the medicine's full risk profile is still being established. There is no legitimate route to obtain retatrutide in the UK outside participation in an authorised trial. If you are concerned about weight management and would like to explore options that are currently available, speaking with your GP is the appropriate first step, as licensed treatments do exist and can be assessed based on your individual circumstances.

Frequently Asked Questions